Reversibility of hepatic fibrosis;Reversibiliteit van leverfibrose

Nederlands Tijdschrift voor Geneeskunde

Volumn 158, Issue 16, 2014, Pages

  Van Der Meer, Adriaan J ^a,b   Sonneveld, Milan J ^a   Schouten, Jeoffrey N L ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IJSSELLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEPATITIS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; SURVIVAL RATE; COMPLICATION; CONVALESCENCE; DISEASE COURSE; FEMALE; LIVER DISEASE; MALE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX;

EID: 84899411245     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver D. Liver biopsy. Hepatology. 2009;49:1017-44.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64.
3. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-13. (Pubitemid 34465173)
4. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-24. (Pubitemid 30171890)
5. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-38.
6. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149:399-403.
7. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-93.
8. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.
9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-52.
10. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-75.
11. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-93.
12. Papatheodoridis GV, Petraki K, Cholongitas E, Kanta E, Ketikoglou I, Manesis EK. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2005;12:199-206. (Pubitemid 40342179)
13. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:1945-53.
14. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740-9. (Pubitemid 38736339)
15. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23.
16. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969-74.
17. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532-40.
18. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-54. (Pubitemid 38702666)
19. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-4. (Pubitemid 32900577)
20. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23-8. (Pubitemid 38938715)
21. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
22. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis - early abstinence is a key factor in prognosis, even in the most severe cases. Addiction. 2009;104:768-74.
23. Desmet VJ, Roskams T. Reversal of cirrhosis: evidence-based medicine? Gastroenterology. 2003;125:629-30, author reply 30-31.
24. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-47.
25. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760-5.